InspireMD, Inc. (NASDAQ:NSPR) is a medical device company focused on developing innovative solutions for neurovascular care. Its main activity is creating and selling its CGuard family of products. These advanced medical devices are designed to prevent strokes in patients undergoing procedures to treat blocked carotid arteries, which supply vital blood to the brain.
On May 4, 2026, NSPR reported its first-quarter financial results. The company announced an earnings per share (EPS) of -$0.16. This result significantly beat the analyst consensus estimate of -$0.19 per share, as highlighted by Zacks. It also shows a notable improvement from the loss of $0.22 per share reported in the same quarter a year ago, indicating progress in its financial performance.
The company also posted strong revenue of approximately $3.4 million for the quarter. This impressive figure surpassed the consensus estimate of $2.7 million by over 25%. As reported by GlobeNewswire, this robust revenue marks a 122% increase year-over-year, primarily driven by rising demand for its CGuard Prime and original CGuard products in the neurovascular market.
Despite strong sales growth, NSPR is not yet profitable, showing a trailing price-to-earnings (P/E) ratio of -2.07. A negative P/E ratio indicates a company has had a net loss over the past year. This is further reflected in its earnings yield of -48.36%, which measures the loss generated per dollar invested in the stock, highlighting current profitability challenges.
Looking at other key financial metrics, NSPR has a price-to-sales (P/S) ratio of 5.06. This ratio compares the company's stock price to its revenues, offering insight into its valuation relative to sales. The company also received crucial FDA approval to begin a new clinical trial and anticipates further product approvals later in 2026, which could significantly increase its addressable market and drive future growth in the medical device sector.
